List of Excipients in Branded Drug CEFOTAN

Cefotan Excipient Strategy and Commercial Opportunities for Cefotetan Injection

Last updated: August 3, 2026

Cefotan is the brand name for cefotetan disodium, a parenteral cephamycin antibiotic used primarily for perioperative prophylaxis and selected intra-abdominal, gynecologic, skin, and urinary tract infections. The product’s original formulation is a sterile powder for intravenous or intramuscular administration, with cefotetan disodium and sodium carbonate as the principal formulation components. Its commercial opportunity is therefore concentrated in generic sterile injectables, hospital supply reliability, low-particulate reconstitution, sodium-management positioning, and differentiated ready-to-use presentations rather than new-molecule patent protection.

What is Cefotan and how is it formulated?

Cefotan contains cefotetan disodium, a beta-lactam antibacterial related structurally to the cephalosporins. The marketed dosage forms are sterile powders supplied in single-dose vials for reconstitution before administration [1].

Attribute	Cefotan profile
Active ingredient	Cefotetan disodium
Drug class	Cephamycin beta-lactam
Primary route	Intravenous; intramuscular use is also described
Common vial strengths	1 g and 2 g cefotetan-equivalent presentations
Primary excipient	Sodium carbonate
Preservative	No preservative in the standard single-dose powder presentation
Main use settings	Surgical prophylaxis and hospital treatment
Regulatory pathway	Small-molecule NDA and ANDA pathways
Biosimilar relevance	None
Principal formulation challenge	Chemical stability and reconstitution performance

The formulation is intentionally simple. A dry powder reduces the stability burden associated with an aqueous beta-lactam solution. Sodium carbonate provides an alkaline microenvironment and supports the salt form used for manufacture and reconstitution. The formulation does not require a complex lipid, polymer, surfactant, or lyophilized excipient system.

What excipients are used in Cefotan?

The core excipient is sodium carbonate. The cefotetan disodium salt also contributes sodium to the final preparation. Product labeling identifies the sodium load as clinically relevant, particularly for patients requiring sodium restriction [1].

The excipient strategy has four functional objectives:

1. Maintain cefotetan stability during storage.
2. Produce a rapidly dissolving sterile powder.
3. Control the pH of the reconstituted solution.
4. Support compatibility with approved diluents and common hospital administration systems.

The absence of antimicrobial preservatives is commercially important. A preservative-free single-dose vial reduces concerns about benzyl alcohol, parabens, phenol, or other excipient sensitivities. It also aligns with standard hospital practice for injectable beta-lactams.

What formulation patents protect Cefotan?

Cefotan’s original commercial protection is not materially dependent on a current formulation-patent estate. The principal active-ingredient and product-specific exclusivity periods for cefotetan are historic, and generic manufacturers can generally pursue cefotetan injection through the ANDA pathway if they satisfy pharmaceutical-equivalence, bioequivalence, chemistry, manufacturing, and controls requirements.

The relevant intellectual-property categories are:

IP category	Commercial relevance for Cefotan
Cefotetan compound patents	Expired or no longer a practical barrier to ordinary generic entry
Original formulation patents	Historic value; limited current blocking effect
Method-of-use patents	Limited value for established hospital indications
Manufacturing patents	Potentially relevant where a supplier uses a protected process, impurity-control method, or crystallization method
Container-closure patents	Possible protection for proprietary ready-to-use packaging, but not for the basic vial concept
Device patents	Relevant only to differentiated delivery systems
Trade secrets	Potential value in yield, impurity control, sterile filling, and shelf-life performance

FDA’s Orange Book remains the primary source for listed patents and regulatory exclusivity associated with approved drug products [2]. For a mature injectable such as cefotetan, commercial diligence should focus less on Orange Book blocking patents and more on manufacturing capacity, drug-shortage exposure, supplier qualification, and technical transfer risk.

When does Cefotan lose exclusivity?

Cefotetan lost the commercial value of new-molecule exclusivity and primary patent protection years ago. It is a mature small-molecule injectable, not a product approaching an upcoming loss-of-exclusivity event.

The practical exclusivity position is:

Exclusivity type	Cefotetan position
New chemical entity exclusivity	Expired
Basic compound patent protection	Expired or commercially immaterial
Current pediatric exclusivity	Not a meaningful barrier
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Formulation exclusivity	No known broad barrier to conventional generic cefotetan powder
ANDA market exclusivity	Possible only for a qualifying first applicant and product-specific regulatory circumstances

Cefotetan is therefore best analyzed as a commodity or constrained-supply sterile injectable rather than a protected branded asset.

What is the FDA regulatory status of Cefotan?

The original Cefotan product was approved as an injectable cefotetan product. Current commercial availability should be separated into three categories:

1. The historical branded Cefotan product.
2. Approved generic cefotetan injection products.
3. Hospital or distributor inventory under changing NDC ownership.

FDA approval does not guarantee continuous commercial supply. Injectable antibiotics can leave the market because of manufacturing economics, quality-system remediation, raw-material constraints, or low-volume procurement. FDA’s Drugs@FDA database, the Orange Book, and the FDA Drug Shortages database should be reviewed together when assessing current availability [2,3].

Is Cefotan listed in the Orange Book?

The Orange Book is relevant for the approved drug application and any listed patents or exclusivity. For mature cefotetan injection products, the commercial analysis is generally not driven by an active patent listing. The absence of a meaningful Orange Book patent barrier does not eliminate regulatory risk. An ANDA sponsor must still demonstrate equivalence and manufacture the product under current good manufacturing practice requirements.

The most important regulatory variables are:

• Sterility assurance.
• Assay and degradation-product control.
• Reconstitution time.
• Visible and subvisible particulate control.
• Container-closure integrity.
• In-use stability.
• Labeling of sodium content.
• Compatibility with approved diluents.
• Demonstration of equivalent dosage form and route.

What excipient strategy offers the best commercial opportunity?

The strongest strategy is to preserve the simple powder formulation while improving operational performance. Adding excipients without a clear stability or administration benefit could increase regulatory burden and create avoidable differentiation risk.

Strategy 1: Optimize sodium carbonate concentration

Sodium carbonate is central to the existing formulation, but its level can be optimized for:

• Reconstitution speed.
• Final solution pH.
• Cefotetan degradation control.
• Cake or powder morphology.
• Sodium burden.
• Manufacturing robustness.

A lower-sodium formulation could have commercial value if it maintains stability and dissolution performance. The opportunity is limited by the contribution of the disodium active ingredient itself. Excipient optimization cannot remove all sodium from cefotetan disodium.

Strategy 2: Improve powder morphology

A controlled crystallization or drying process could produce a powder with:

• Lower aggregation.
• Faster wetting.
• Reduced vial-wall residue.
• More consistent withdrawal volumes.
• Lower risk of incomplete dissolution.

This approach is more likely to generate defensible know-how than a broad new excipient claim. Process control, particle-size distribution, residual moisture, and impurity profiles can create manufacturing advantages even when the public formulation is simple.

Strategy 3: Develop a ready-to-use liquid

A ready-to-use cefotetan solution could reduce pharmacy preparation time and improve administration convenience. The technical barrier is chemical stability. A liquid presentation would require control of:

• pH.
• Temperature exposure.
• Oxygen exposure.
• Container interaction.
• Light sensitivity.
• Freeze-thaw behavior.
• In-use dating.
• Compatibility with infusion bags and administration sets.

A ready-to-use product could command a premium in operating rooms, ambulatory surgery centers, and hospitals with centralized pharmacy operations. The formulation would carry higher development and manufacturing costs than a dry powder.

Strategy 4: Use polymeric or nonaqueous stabilization

Polyols, buffering systems, or nonaqueous vehicles could be evaluated for liquid stability, but each introduces regulatory and clinical compatibility issues. The commercial case would need to justify:

• Better shelf life.
• Fewer preparation steps.
• Reduced medication errors.
• Lower pharmacy labor.
• Lower wastage.

For a low-cost mature antibiotic, an elaborate excipient system is unlikely to be attractive unless it supports a ready-to-administer product with a clear institutional purchasing advantage.

Strategy 5: Package the powder for rapid reconstitution

A vial-and-diluent configuration, dual-chamber system, or transfer device could create practical differentiation without changing the active ingredient. The most commercially relevant options include:

• Premeasured diluent presentations.
• Dual-chamber bags.
• Closed-system transfer devices.
• Ready-to-mix pharmacy containers.
• Barcoded unit-dose packaging.
• Larger institutional vial formats.

These products may be protected through device, packaging, or process claims rather than conventional composition patents.

What formulations are protected or commercially differentiable?

The principal formulation types are shown below.

Formulation	Benefit	Main limitation	Commercial assessment
Conventional dry powder vial	Low manufacturing complexity and good storage stability	Requires pharmacy reconstitution	Lowest-cost generic baseline
Dry powder with supplied diluent	Simplifies preparation	Higher packaging and logistics cost	Attractive for surgery centers
Ready-to-use liquid vial	Eliminates reconstitution	Stability and cold-chain burden	Premium opportunity if shelf life is adequate
Ready-to-use infusion bag	Reduces pharmacy handling	Higher container and stability complexity	Strong hospital workflow proposition
Dual-chamber system	Separates unstable components until use	Device development and validation	Defensible differentiated product
Extended-stability liquid	Supports decentralized use	Requires extensive stability data	Potentially valuable for outpatient settings

A conventional generic can compete on price. A differentiated product must compete on total treatment-system cost, including pharmacy labor, preparation time, product wastage, medication errors, and inventory management.

How strong is the Cefotan patent estate?

The patent estate is weak as a barrier to conventional generic cefotetan injection. The stronger commercial barriers are technical and operational.

Barrier	Relative strength
Active-ingredient patent barrier	Low
Conventional powder formulation barrier	Low
Basic sodium-carbonate formulation barrier	Low to moderate, depending on claim scope and jurisdiction
Sterile manufacturing capability	Moderate to high
Cefotetan API supply	Moderate
Impurity and degradation control	Moderate
Ready-to-use liquid development	Moderate to high
Hospital contracting and qualification	Moderate
Supply continuity	High in constrained markets

A company seeking differentiated protection should target a specific, measurable improvement. Examples include a defined impurity profile, a particular reconstitution time, a validated stability period, a dual-chamber configuration, or a process that materially improves yield and batch consistency.

Broad claims covering cefotetan with a conventional buffer or excipient are likely to face novelty, obviousness, enablement, or written-description challenges.

Which companies are challenging Cefotan exclusivity?

The relevant challengers are generic injectable manufacturers rather than biosimilar developers. Cefotetan is a small molecule, so the applicable pathway is an ANDA, not a 351(k) biosimilar application.

Potential competitive groups include:

• Established U.S. generic injectable manufacturers.
• Contract manufacturers with beta-lactam sterile-filling capability.
• International cephalosporin suppliers seeking U.S. approval.
• Hospital-focused suppliers with institutional contracting infrastructure.
• Specialty distributors that acquire or license mature injectable products.

A Paragraph IV challenge is less commercially important for an old cefotetan product if no meaningful listed patent blocks approval. The more likely pathway is a paragraph I, II, or III certification, depending on the Orange Book record and the status of listed patents. Any specific litigation assessment must be tied to the relevant NDA, ANDA, patent number, and court docket.

What patent litigation affects Cefotan?

No major, widely recognized current patent-litigation narrative defines cefotetan injection in the same way that litigation affects protected branded products such as high-value oncology, immunology, or metabolic therapies. The practical legal issues are more likely to involve:

• ANDA product approval.
• Manufacturing-site compliance.
• Contract manufacturing agreements.
• Supply and distribution rights.
• Product liability.
• Quality recalls.
• Antitrust or contracting disputes.
• Trade-secret claims involving sterile manufacturing or impurity control.

A settlement agreement is unlikely to be the central commercial variable for a mature cefotetan product. Generic entry timing will generally depend on FDA approval, manufacturing readiness, and commercial launch economics rather than negotiated patent delay.

What generic entry risks exist for Cefotan?

Generic entry risk is high for the conventional powder vial because the underlying active ingredient is mature and the formulation is relatively simple. However, the number of effective competitors may remain limited if the market is small or manufacturing is difficult.

Generic launch scenarios

Scenario	Likely result
Multiple approved powder-vial suppliers	Price erosion and low margins
One or two reliable suppliers	Stable pricing with supply premiums
Brand discontinuation plus limited generic supply	Shortage-driven opportunity
New ready-to-use entrant	Premium pricing and hospital workflow differentiation
API disruption	Allocation, backorders, and rapid price increases
Manufacturing warning letter	Reduced supply and customer switching

The principal risk is not merely generic substitution. It is a structurally thin supply base. A low-price product can become commercially attractive when hospitals prioritize continuity of supply and when competing suppliers experience quality or capacity problems.

What manufacturing and IP barriers affect commercial entry?

Cefotetan manufacturing has several technical requirements that can limit entry:

• Sourcing pharmaceutical-grade cefotetan API.
• Controlling beta-lactam cross-contamination.
• Validating sterile powder filling.
• Managing moisture sensitivity.
• Controlling degradation products.
• Demonstrating container-closure integrity.
• Establishing reconstitution and in-use stability.
• Validating compatibility with diluents.
• Meeting compendial and microbiological requirements.

Beta-lactam manufacturing may require dedicated or appropriately segregated facilities. That requirement can deter manufacturers that lack suitable containment and cleaning-validation systems.

The most defensible IP opportunities are process and presentation claims. Trade secrets may also have higher value than patents where the advantage depends on crystallization conditions, drying parameters, impurity purge, or filling controls.

How does Cefotan compare with competing injectable antibiotics?

Cefotetan competes with other perioperative and hospital-administered beta-lactams, including cefazolin, cefoxitin, ceftriaxone, cefuroxime, and selected broader-spectrum agents.

Product	Commercial positioning	Excipient opportunity
Cefotetan	Cephamycin with surgical and anaerobic coverage	Sodium management, reconstitution, ready-to-use delivery
Cefazolin	High-volume surgical prophylaxis	Scale, low cost, premixed systems
Cefoxitin	Cephamycin comparator	Similar sterile-powder and stability opportunities
Ceftriaxone	Broad hospital and outpatient use	Diluent compatibility and ready-to-use formats
Cefuroxime	Perioperative and respiratory use	Powder stability and device packaging

Cefotetan is less attractive than high-volume cefazolin for a pure scale strategy. It may be more attractive as part of a portfolio covering hospital antibiotics, where shared sterile manufacturing, sales infrastructure, and procurement relationships reduce incremental cost.

What licensing deals could create value?

Licensing opportunities are most credible in four areas:

1. A U.S. marketing authorization for an approved or near-approved cefotetan injectable.
2. A ready-to-use formulation with validated shelf life.
3. A dual-chamber or closed-transfer presentation.
4. A reliable cefotetan API and sterile-filling supply chain.

A license should be evaluated against:

• ANDA ownership.
• FDA approval status.
• Remaining regulatory commitments.
• NDC and listing status.
• Manufacturing-site history.
• Supply agreement duration.
• API source qualification.
• Hospital contract coverage.
• Recall and shortage history.
• Freedom to operate for packaging and process claims.

A buyer should avoid paying a branded-product premium for a mature product whose value comes mainly from supply continuity. The appropriate valuation basis is typically contribution margin, contracted volume, manufacturing reliability, and working-capital requirements.

What revenue exposure does Cefotan create?

Public sources do not establish a reliable current revenue figure for Cefotan as a standalone brand. Revenue exposure is better assessed through volume and price variables:

• Annual vial demand.
• Mix between 1 g and 2 g presentations.
• Surgical prophylaxis share.
• Hospital contract concentration.
• Average selling price.
• Gross margin after sterile manufacturing costs.
• Inventory write-off risk.
• Shortage-related volume volatility.

The highest-value commercial model is usually not a premium branded vial. It is a reliable institutional supply product with differentiated packaging, predictable lead times, and lower pharmacy handling costs.

Key Takeaways

• Cefotan is cefotetan disodium, a mature small-molecule injectable antibiotic.
• Sodium carbonate is the principal named excipient in the conventional powder formulation.
• The basic Cefotan formulation has limited current patent-blocking value.
• Biosimilar risk does not apply; generic ANDA competition is the relevant pathway.
• The strongest commercial opportunities are ready-to-use liquid or infusion presentations, dual-chamber packaging, rapid reconstitution, and reliable sterile supply.
• Manufacturing capability, beta-lactam segregation, impurity control, and hospital contracting are more important barriers than basic composition patents.
• A conventional generic powder vial faces high price competition.
• A differentiated delivery system can support premium pricing if it reduces pharmacy labor, preparation risk, or product wastage.
• Licensing value should be based on supply continuity, approval status, manufacturing readiness, and institutional contracts rather than historic Cefotan branding.

FAQs

Is Cefotan the same drug as cefotetan?

Yes. Cefotan is a brand presentation of cefotetan disodium for injection.

Does cefotetan contain preservatives?

The standard single-dose Cefotan powder presentation is preservative-free. Sodium carbonate is used as a formulation component.

Can a company launch generic cefotetan without challenging a patent?

Yes, if the relevant regulatory and Orange Book record does not contain an unexpired patent that requires a Paragraph IV certification. The applicant must still meet FDA ANDA requirements.

Is a low-sodium cefotetan formulation commercially feasible?

It may be feasible as a formulation-development objective, but cefotetan disodium itself contributes sodium. The commercial value depends on whether sodium reduction can be achieved without compromising stability, dissolution, or equivalence.

What is the most defensible IP for a new cefotetan product?

The strongest candidates are specific ready-to-use formulations, validated stability profiles, dual-chamber delivery systems, reconstitution technologies, and manufacturing processes that improve impurity control or batch yield.

References

1. U.S. Food and Drug Administration. (n.d.). Cefotan (cefotetan disodium) for injection prescribing information. FDA-approved product labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Drug shortages database. FDA Drug Shortages Staff.

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content and format. FDA, Center for Drug Evaluation and Research.